Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03499795
Recruitment Status : Recruiting
First Posted : April 17, 2018
Last Update Posted : April 16, 2019
Sponsor:
Information provided by (Responsible Party):
Inovio Pharmaceuticals

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : March 2021
  Estimated Study Completion Date : March 2021